STANDARD BIOTOOLS INC. (LAB) Financials
Annual revenue, profitability and per-share results for STANDARD BIOTOOLS INC., as reported in SEC filings.
Revenue • FY2025
$85.33M
▼ 51.1%YoY
Net income • FY2025
-$74.9M
▲ 46.1%YoY
Gross margin • FY2025
49.9%
Diluted EPS • FY2025
-$0.20
▲ 61.5%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $85.33M | -$74.9M | $42.54M | -$0.20 | -$82.65M | -129.2% | -51.1% |
| FY2024 | $174.43M | -$138.88M | $84.26M | -$0.52 | -$151.81M | -100.5% | +64.0% |
| FY2023 | $106.34M | -$74.66M | $50.45M | -$0.94 | -$46.12M | -72.0% | +8.6% |
| FY2022 | $97.95M | -$190.1M | — | -$2.43 | -$93.19M | -118.6% | -25.0% |
Figures as reported in STANDARD BIOTOOLS INC.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a LAB filing.
Get an email when LAB files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.